Amgen Inc. v. Connecticut Retirement Plans and Trust Funds

Target entity: Amgen Inc. v. Connecticut Retirement Plans and Trust Funds
Context triple: [Basic Inc. v. Levinson, influencedCase, Amgen Inc. v. Connecticut Retirement Plans and Trust Funds]

• A. Association for Molecular Pathology v. Myriad Genetics, Inc.
  Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
• B. Mayo Collaborative Services v. Prometheus Laboratories, Inc.
  Mayo Collaborative Services v. Prometheus Laboratories, Inc. is a landmark 2012 U.S. Supreme Court case that limited the patentability of medical diagnostic methods by holding that laws of nature and their routine applications are not eligible for patent protection.
• C. Medtronic, Inc. v. Mirowski Family Ventures, LLC
  Medtronic, Inc. v. Mirowski Family Ventures, LLC is a 2014 U.S. Supreme Court case that clarified the burden of proof in patent licensee declaratory judgment actions, holding that the patent holder—not the licensee—bears the burden of proving infringement.
• D. Halliburton Co. v. Erica P. John Fund, Inc.
  Halliburton Co. v. Erica P. John Fund, Inc. is a 2014 U.S. Supreme Court securities fraud case that reaffirmed but modified the “fraud-on-the-market” presumption of reliance in class action lawsuits.
• E. United States v. Gementera
  United States v. Gementera is a federal appellate case known for upholding a controversial shaming-based condition of supervised release imposed on a mail thief, raising significant debate about the limits of creative sentencing under the Eighth Amendment.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Amgen Inc. v. Connecticut Retirement Plans and Trust Funds
Target entity description: Amgen Inc. v. Connecticut Retirement Plans and Trust Funds is a 2013 U.S. Supreme Court securities fraud case that held plaintiffs need not prove the materiality of alleged misstatements at the class certification stage.

• A. Association for Molecular Pathology v. Myriad Genetics, Inc.
  Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
• B. Mayo Collaborative Services v. Prometheus Laboratories, Inc.
  Mayo Collaborative Services v. Prometheus Laboratories, Inc. is a landmark 2012 U.S. Supreme Court case that limited the patentability of medical diagnostic methods by holding that laws of nature and their routine applications are not eligible for patent protection.
• C. Medtronic, Inc. v. Mirowski Family Ventures, LLC
  Medtronic, Inc. v. Mirowski Family Ventures, LLC is a 2014 U.S. Supreme Court case that clarified the burden of proof in patent licensee declaratory judgment actions, holding that the patent holder—not the licensee—bears the burden of proving infringement.
• D. Halliburton Co. v. Erica P. John Fund, Inc.
  Halliburton Co. v. Erica P. John Fund, Inc. is a 2014 U.S. Supreme Court securities fraud case that reaffirmed but modified the “fraud-on-the-market” presumption of reliance in class action lawsuits.
• E. United States v. Gementera
  United States v. Gementera is a federal appellate case known for upholding a controversial shaming-based condition of supervised release imposed on a mail thief, raising significant debate about the limits of creative sentencing under the Eighth Amendment.
• F. None of above. chosen